Clinical Trials Logo

Pediatric Hypertension clinical trials

View clinical trials related to Pediatric Hypertension.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03461003 Completed - Clinical trials for Pediatric Hypertension

N-of-1 Trials In Children With Hypertension

NICHE
Start date: April 2, 2018
Phase: Phase 4
Study type: Interventional

The single patient (n-of-1) randomized trial is an underused approach to resolving therapeutic uncertainty by using a patient's own data to inform an individualized treatment plan. The proposed research is designed to assess whether the n-of-1 trial approach improves blood pressure control compared to usual care. This trial aims to advance learning about not only the treatment of pediatric hypertension but also the use of a neglected type of randomized trial to optimize the care of each patient.

NCT ID: NCT02791438 Completed - Clinical trials for Pediatric Hypertension

A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Start date: August 18, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety of administration of azilsartan in pediatric patients aged 6 to less than 16 years with hypertension.

NCT ID: NCT02451150 Completed - Clinical trials for Pediatric Hypertension

A Phase 3 Pharmacokinetic Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Start date: August 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of TAK-536 in pediatric patients aged 6 to less than 16 years with hypertension.

NCT ID: NCT00244634 Completed - Clinical trials for Pediatric Hypertension

Atacand Dose Range Finding Study in Pediatric Subjects 6 to <17 Years of Age

Start date: September 2003
Phase: Phase 3
Study type: Interventional

Study 261A is a dose-ranging and safety study of candesartan cilexetil. It is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study with a 4 week treatment period in hypertensive pediatric subjects. Subjects undergo a screening evaluation, then a 1-week, single-blind, placebo run-in after which eligible subjects are allocated to receive 1 of 3 dose levels of candesartan cilexetil or placebo. The study includes 2 panels based on subject weight. The primary efficacy analysis is based on the intent-to-treat population and tests for slope = 0 in a linear regression model with change in sitting systolic blood pressure as the dependent and non-zero dose pooled across weight panels as the independent variable. For subjects without a Double-Blind Week 4 blood pressure determination, carrying the last value forward assigns the value. Additional analyses will include data pooled from a similar dose ranging study conducted in children 1 to < 6 years of age.